Eli Lilly reduced Zepbound vial prices for self-paying patients via LillyDirect, aiming to lower obesity treatment costs and improve access. Price reductions include $50 off the 2.5 mg vial and $100 ...

Eli Lilly is cutting introductory Zepbound prices again, with the lowest dose now $299 monthly for cash-pay customers, a $50 ...

LillyDirect is a legitimate, direct-to-consumer platform that offers authentic Eli Lilly medication. This platform accepts insurance and offers self-pay options. LillyDirect is partnered with licensed ...

On the heels of striking a deal with the Trump administration to reduce the prices of several of its most popular drugs for U.S. patients, Eli Lilly has unveiled additional savings for cash-paying ...

This is the second time Eli Lilly has cut prices of Zepbound on LillyDirect. The pharmaceutical company said it is making the ...

Eli Lilly is cutting what self-paying patients shell out for its blockbuster obesity drug Zepbound when they buy single-dose ...

With a valid prescription, patients can access the starting dose of Zepbound single-dose vial (2.5 mg) for as low as $299 per month from $349. The 5 mg dose will be available at $399 per month, down ...

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up with rival Novo Nordisk A/S.

The decision is the latest in a series of moves to make its GLP-1 blockbuster more widely available and affordable.

Some patients dropped out of the trial early because they had lost so much weight.